EVO ICL HK

20/03/2024

🎉百萬里程譜新篇 🎉
🎊ICL晶體植入量全球突破300萬🎊
美國時間2024年3月18日，專注於眼科醫療產品的設計、研發和製造的STAAR Surgical公司 (NASDAQ: STAA) 宣佈ICL全球植入量超過300萬枚(1)。
STAAR Surgical總裁兼首席執行官Tom Frinzi表示：「在我們慶祝300萬枚里程碑之際，我謹代表STAAR Surgical公司衷心感謝各位醫生和醫務人員以及選擇ICL矯正視力的各位患者。EVO ICL引領近視矯正技術變革，優勢顯著，患者滿意度高，必將幫助更多近視患者擺脫隱形眼鏡和框架眼鏡的困擾，成為視力矯正的主流。」
EVO ICL是一種可植入式晶體，旨在通過微創手術，滿足各類視力矯正需求，包括近視和散光。EVO ICL晶體植入術，不切削角膜，可快速植入在虹膜（眼睛的有色部分）和自然晶狀體之間。EVO ICL晶體含有膠原蛋白，具有生物相容性，可與人的眼睛和諧共處。如果患者未來需要做其他眼部手術，EVO ICL晶體還可由醫生取出。近視是一種常見的全球流行性屈光不正，預計到2050年，近視將影響全球約50%的人口(2)。
（數據來源：Ophthalmology 2016;123:1036-1042 © 2016 by the American Academy of Ophthalmology）
(1) EVO ICL accounts for approximately 2.5 million of the 3 million total ICLs sold.
(2) Ophthalmology 2016;123:1036-1042 © 2016 by the American Academy of Ophthalmology.

07/11/2022

“It is common for my patients to achieve 1 to 2 line gains of
their BCVA after surgery with the EVO ICL. The quality of
vision that my patients have reported, in my opinion, could
certainly be better than what they could ever achieve with
a laser vision correction procedure.” by SHELDON HERZIG, MD, FRCSC, DABO

Thanks for visiting CRSTEurope. Our advertisers are important supporters of this site, and content cannot be accessed if ad-blocking software is activated.

29/10/2022

10/09/2022

中秋節快樂🌕

08/09/2022

What happens soon🥳
STAAR Surgical and Joe Jonas Team Up to Introduce New Life-Changing EVO ICL to Millions of Americans Suffering from Distance Vision Problems👏🏻
Joe Jonas to Share his Experience with EVO in a Global Campaign that Highlights his Personal Journey to Achieve Visual Freedom👀

25/08/2022

Tonight, at 7:30, join our webinar through ZOOM: 83129020115. Sharing with you our experiences and confidence for over 20 years with ICL. 💖

08/06/2022

Join us in our upcoming Webinar
Zoom：https://us04web.zoom.us/j/75195721472?pwd=VsaoNexaGz9CmHxsbGnsL10I2x1N8H.1
😍😍

14/02/2021

Happy Valentins Day🥰🥰🥰🥰

11/02/2021

高清視界，自由追尋。
凜冬散盡，共看花開！
2021，新年快樂！
瞭解更多關於EVO ICL 同EVO+ICL，歡迎訪問我們：https://staar.com/products/evo-plus-visian-icl

14/10/2020

frequently asked questions about EVO ICL